Legal Battle of the Bio-Eggs: Delaware Court Dismisses Onego Bio’s Suit Against The EVERY Co.

In a definitive conclusion to a high-stakes, multi-jurisdictional legal saga that has gripped the food-tech industry for over a year, a Delaware district court has dismissed a patent-related lawsuit filed by Finnish precision fermentation firm Onego Bio against California-based The EVERY Company. The dismissal marks the end of an aggressive, headline-grabbing dispute between two of the sector’s most prominent players, both of whom are vying to revolutionize the global egg market through animal-free, bio-identical proteins.

The ruling, delivered by U.S. District Judge Joshua D. Wolson on October 9, brings to a close a narrative characterized by allegations of corporate bullying, strategic patent warfare, and failed merger negotiations. While the court stopped short of ruling on the technical merits of the patents in question, the judicial language was pointed, characterizing Onego Bio’s legal maneuverings as an attempt to "egg" a competitor into a fight—one that The EVERY Co. persistently sought to avoid.

The Core of the Conflict: A Clash of Technologies

At the heart of the dispute is the production of ovalbumin, the primary protein found in egg whites. Both companies utilize precision fermentation—a process that uses engineered microbes to produce proteins identical to those found in conventional eggs, without the need for poultry.

The dispute centered on U.S. Patent No. 12,096,784 (the ‘784 patent), held by The EVERY Co. The patent covers the expression of ovalbumin in various microbial hosts. Onego Bio, which utilizes a specific strain of the fungus Trichoderma reesei for its production process, argued that the patent was overly broad, invalid, and unenforceable. Onego maintained that it initiated the lawsuit to "clear the cloud" of uncertainty surrounding its business, claiming that The EVERY Co. was using its patent portfolio as a "strategic weapon" to stifle competition and intimidate potential investors.

Conversely, The EVERY Co. has maintained from the outset that its intellectual property is the result of over a decade of intensive R&D. They argued that they never sought litigation and that their interactions with Onego were characterized by efforts to de-escalate tensions and explore potential business synergies, including past discussions regarding a possible merger.

Chronology of a Failed Partnership

The relationship between the two companies was not always litigious. Court documents reveal that before the legal battle erupted in late 2024, the firms were in discussions that touched upon potential collaboration and even a merger. However, when those talks broke down, the dynamic shifted from potential partnership to adversarial posturing.

• Mid-2024: Tensions rise as The EVERY Co. asserts its intellectual property rights, and Onego Bio claims that EVERY is misrepresenting the risk of infringement to investors.
• Late 2024: Onego Bio initiates a lawsuit in the U.S. District Court for the District of Delaware, seeking a declaratory judgment that it is not infringing on the ‘784 patent and that the patent itself is invalid.
• May 2025: A parallel lawsuit filed by Onego Bio against The EVERY Co. in Wisconsin is dismissed, serving as a precursor to the final decision in Delaware.
• October 9, 2025: Judge Joshua D. Wolson issues a memorandum and order dismissing the Delaware case, citing a lack of subject matter jurisdiction and noting that Onego failed to prove that a justiciable controversy existed.

Judicial Perspective: The Instigator vs. The De-escalator

The most damaging aspect of the ruling for Onego Bio was the judge’s characterization of the parties’ conduct. Judge Wolson’s order explicitly stated that the evidence failed to support the notion that The EVERY Co. had engaged in actionable threats.

"The evidence before me doesn’t show that EVERY did anything to assert its rights against Onego," the judge wrote. "On the contrary, the facts make clear that Onego played the instigator. But picking a fight with a perceived competitor isn’t enough to establish declaratory judgment jurisdiction."

The court also dismissed Onego’s claims regarding false advertising. Onego had alleged that The EVERY Co. made deceptive statements about its products being "bio-identical" to chicken eggs. However, the court found that because Onego is not yet fully operational in the U.S. market, it lacked the standing to claim that it had suffered competitive injury. As the judge noted, "Absent ongoing operations, it is not plausible that Onego and EVERY are competitors in the same market space."

Regarding claims that The EVERY Co.’s CEO, Arturo Elizondo, had discouraged potential investors from backing Onego, the court found the evidence insufficient. Mr. Elizondo denied making such statements, and the court ruled that the hearsay evidence provided by Onego representatives—who were not present during the alleged conversations—held little to no probative value.

Implications for the Food-Tech Sector

The dismissal has sent shockwaves through the precision fermentation industry, highlighting the complexities of navigating IP in a nascent market.

For The EVERY Co.: A Vindicated Strategy

The EVERY Co. has positioned the ruling as a complete vindication of their business model. In a statement provided to AgFunderNews, the company expressed gratitude for the court’s "careful review" and reaffirmed its commitment to defending its intellectual property. By successfully fending off a preemptive strike on its patent, The EVERY Co. maintains its position as a dominant player with a secure and enforceable moat around its core technology.

For Onego Bio: Spinning a "Clear" Future

Despite the dismissal, Onego Bio has adopted a surprisingly optimistic tone, claiming the ruling provides "clarity." CEO Maija Itkonen emphasized that the court found no infringement claim against Onego and that the litigation is officially behind them.

Onego is also pivoting to a global strategy, pointing out that patent offices in Japan, South Korea, and the European Patent Office have either rejected or raised significant objections to counterpart applications from The EVERY Co. This suggests that while Onego may have lost the battle in Delaware, it intends to continue its broader strategy of challenging the validity of the EVERY patent family on an international stage.

The Broader Landscape: Challenges and Opportunities

This legal fight serves as a microcosm of the growing pains currently experienced by the alternative protein industry. As companies move from the laboratory to commercial-scale production, the stakes regarding "freedom to operate" become existential.

1. Intellectual Property Protection: For startups, securing a defensible IP position is the primary driver of valuation. However, as demonstrated by this case, using litigation as a tool to gain market advantage is a high-risk strategy that can backfire under judicial scrutiny.
2. Market Maturity: The court’s note that Onego and EVERY were not yet "competitors in the same market space" highlights a critical issue: many companies in this sector are still in the pre-revenue or early-commercialization phase. Until these companies are consistently shipping product at scale, legal battles may be premature or legally unsustainable.
3. The "Bio-identical" Debate: The underlying scientific question—whether precision-fermented proteins are truly bio-identical to their animal counterparts—remains a flashpoint for industry regulation and marketing. While the court sidestepped this, the industry will continue to face scrutiny from regulators and competitors regarding these claims.

Looking Ahead: A Competitive Horizon

As the dust settles, both firms are signaling a return to their primary objective: market dominance. Onego Bio continues to move forward with plans for a manufacturing facility in Wisconsin and claims to be shipping "metric tons" of its Bioalbumen product to customers. Meanwhile, The EVERY Co. continues to expand its portfolio and partnerships with major food conglomerates.

The case of Onego Bio v. The EVERY Co. serves as a cautionary tale for the food-tech sector. It underscores that in the eyes of the court, the courtroom is not a place for "picking fights" or resolving business disputes that could be settled through negotiation. For now, the "egg wars" have concluded, leaving both companies to face the true arbiter of their success: the consumer.

Whether the market has room for multiple players producing ovalbumin via precision fermentation—or whether the ‘784 patent will remain an insurmountable barrier for newcomers—will be determined not by legal filings, but by the efficiency, scalability, and market acceptance of these innovative food technologies. As the industry matures, the focus will likely shift from the courtroom to the grocery aisle, where the battle for the future of the egg will truly be won.